ITRMF · CIK 0001659323
Iterum Therapeutics plc
Annual figures as reported, FY2015–FY2024. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Net income
−$24.8M
▲ +35.4% vs FY2023
Free cash flow
−$26.8M
▲ +32.0% vs FY2023
Diluted EPS
−$1.26
▲ +57.4% vs FY2023
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Sep ’25 quarter
$390K
Net income — Sep ’25 quarter
−$9.0M
▼ −47.3% vs Sep ’24
Revenue — trailing 12 months
$715K
Diluted EPS — trailing 12 months
−$0.70
▲ +64.8% vs Sep ’24
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Sep ’25 | $390K | — | — | −$9.0M | −2302.3% | −$0.20 |
| Mar ’19 | $37K | −80.6% | — | — | — | — |
| Dec ’18 | $239K | — | — | — | — | — |
| Sep ’18 | $254K | 59.7% | — | — | — | — |
| Jun ’18 | $185K | — | — | — | — | — |
| Mar ’18 | $191K | — | — | — | — | — |
| Sep ’17 | $159K | — | — | — | — | — |
Profitability & returns
quality of earningsReturns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Key ratios
derived per fiscal year| Fiscal year | ROE | ROA | Current ratio | Debt / equity |
|---|---|---|---|---|
| FY2024 | — | −55.6% | 1.41× | — |
| FY2023 | — | −146.1% | 1.89× | — |
| FY2022 | −158.7% | −66.5% | 6.89× | 0.45× |
| FY2021 | −182.3% | −100.1% | 6.43× | 0.14× |
| FY2020 | — | −158.6% | 0.51× | — |
| FY2019 | — | −400.5% | 0.32× | — |
| FY2018 | −107.6% | −78.7% | 7.61× | 0.18× |
| FY2017 | −74.5% | −62.9% | 6.20× | 0.00× |
| FY2016 | −59.4% | — | — | — |
| FY2015 | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2024 | — | — | −$18.7M | −$24.8M | −$1.26 | −$26.8M | $2K | $44.6M | $48.7M | −$4.1M | $24.1M | $31.2M |
| FY2023 | — | — | −$47.5M | −$38.4M | −$2.96 | −$39.3M | $13K | $26.3M | $32.7M | −$6.4M | $6.1M | $11.2M |
| FY2022 | — | — | −$30.4M | −$44.4M | −$3.63 | −$18.5M | $62K | $66.8M | $38.8M | $28.0M | $21.1M | $12.7M |
| FY2021 | — | — | −$24.5M | −$91.6M | −$8.41 | −$15.8M | $61K | $91.5M | $41.3M | $50.2M | $27.4M | $6.9M |
| FY2020 | — | — | −$32.1M | −$52.0M | −$32.49 | −$54.5M | $11K | $32.8M | $83.4M | −$50.6M | $14.5M | $22.5M |
| FY2019 | — | — | −$102.0M | −$103.1M | −$7.10 | −$81.9M | $24K | $25.8M | $52.0M | −$26.2M | $4.8M | $7.6M |
| FY2018 | — | — | −$76.6M | −$77.1M | −$8.82 | −$77.3M | $90K | $97.9M | $26.2M | $71.6M | $44.6M | $13.1M |
| FY2017 | — | — | −$29.5M | −$29.4M | −$170.84 | −$30.6M | $812K | $46.8M | $7.2M | $39.5M | $8.5M | $0 |
| FY2016 | — | — | −$13.4M | −$13.5M | −$568.87 | −$11.3M | — | — | — | $22.7M | — | — |
| FY2015 | — | — | — | — | — | — | — | — | — | $14.9M | — | — |
Latest filings
the most recent regulatory filings25-NSEDelisting notice2026-06-23 ↗8-KCurrent report — material event2026-03-31 ↗8-KCurrent report — material event2026-03-27 ↗8-KCurrent report — material event2026-03-03 ↗8-KCurrent report — material event2026-03-02 ↗8-KCurrent report — material event2026-02-18 ↗DEFA14AProxy statement2026-02-13 ↗DEFA14AProxy statement2026-01-26 ↗DEF 14AProxy statement2026-01-02 ↗PRE 14ASEC filing2025-12-23 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.